Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Great. Thank you. Good afternoon. I am Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Karyopharm Therapeutics and presenting on behalf of the company to start us out is CEO, Richard Paulson. (Conference Instructions) So with that, Richard, thanks for joining us.
Thank you, Eric, and thank you to JPMorgan for hosting us today. I'll be joined in the presentation by our Chief Medical Officer, Reshma Rangwala. And then as we evolve into the Q&A, I also have our Chief Commercial Officer, Sohanya Cheng, join us.
Just a little housekeeping before we begin, I'd like to remind you various remarks we make today will constitute forward-looking statements for purposes of Safe Harbor provisions under the Private Securities and Litigation Reform Act of 1995 as you can read in detail on this slide. It's an exciting time at Karyopharm today is Karyopharm's at a turning point and 15-year history with three ongoing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |